The efficacy and toxicity of antineoplastic antimetabolites: Role of gut microbiota. (August 2021)

• Record Type: Journal Article
• Authors: Huang, Xinyi; Chen, Lulu; Li, Zhenyu; Zheng, Binjie; Liu, Na; Fang, Qing; Jiang, Jinsheng; Rao, Tai; Ouyang, Dongsheng
• Is Part Of: Toxicology. Volume 460(2021)
• Publication Date: 2021-08
• Subjects: WHO World Health Organization -- 5-FU 5-flurouracil -- F/B Firmicutes/Bacteroidetes -- CRC colorectal cancer -- 5-FU leucovorin and oxaliplatin, FOLFOX -- CDD cytidine deaminase -- MP mercaptopurine -- TG tioguanine -- IBD inflammatory bowel disease -- AIEC adherent-invasive Escherichia coli -- TGN thioguanine nucleotides -- DHFR dihydrofolate reductase -- MTX methotrexate -- LV leucovorin -- DAMPA 2, 4-diamino-N (10)-methylpteroic acid -- CPDG2 carboxypeptidase glutamate 2 -- PK pharmacokinetics -- SCFA short-chain fatty acids; Antineoplastic antimetabolites -- Cancer -- Individualized medication -- Gut microbiota -- Probiotics; Toxicology -- Periodicals; Chemicals -- Physiological effect -- Periodicals; 615.9005
• DOI: 10.1016/j.tox.2021.152858
• Languages: English
• ISSNs: 0300-483X

Abstract

Graphical abstract: Highlights: Antineoplastic antimetabolites decreased alpha-diversity of gut microbiota. Antineoplastic antimetabolites shifted gut microbiota profiles. Gut microbiota influenced efficacy and toxicity of antineoplastic antimetabolites. Gut microbiota might be new mechanism of individual variation. Abstract: The incidence and mortality of cancer are rapidly growing all over the world. Nowadays, antineoplastic antimetabolites still play a key role in the chemotherapy of cancer. However, the interindividual variations in the efficacy and toxicity of antineoplastic antimetabolites are nonnegligible challenges to their clinical applications. Although many studies have focused on genetic variation, the reasons for these interindividual variations have still not been fully understood. Gut microbiota is reported to be associated with the efficacy and toxicity of antineoplastic antimetabolites. In this review, we summarize the interaction of antineoplastic antimetabolites on gut microbiota and the influences of shifted gut microbiota profiles on the efficacy and toxicity of antineoplastic antimetabolites. The factors affecting the efficacy and toxicity of antineoplastic antimetabolites via gut microbiota are also discussed. In addition, we present our viewpoints that regulating the gut microbiota may increase the efficacy and decrease the toxicity of antineoplastic antimetabolites. This will help us better understand the new mechanism via gut microbiota and promote individualized use of antineoplastic antimetabolites.